Regulatory · source year

2021 regulatory records

29 selected, source-linked regulatory records dated 2021. This is selective source coverage, not a complete timeline.

Dated records

29 selected records.

Peptide profiles

15 connected profiles.

Cited sources

29 distinct public records.

Cited chronology

Dated source records

Open in the filterable feed →

December 2021

5 records

November 2021

3 records

Glucagon + 1 more

Federal Register notice 2021-24431

The Federal Register published notice 2021-24431, attributed to FDA and its parent HHS department, on 2021-11-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Leuprolide.

Source: Federal Register via GovInfo ↗

Afamelanotide

Federal Register notice 2021-24074

The Federal Register published notice 2021-24074, attributed to FDA and its parent HHS department, on 2021-11-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SCENESSE,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide.

Source: Federal Register via GovInfo ↗

October 2021

3 records

September 2021

3 records

Exenatide

Federal Register notice 2021-18928

The Federal Register published notice 2021-18928, attributed to FDA and its parent HHS department, on 2021-09-02. Its official title is “Proposal To Refuse To Approve a New Drug Application for ITCA 650 (Exenatide in DUROS Device); Opportunity for a Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

August 2021

3 records

Leuprolide + 1 more

Federal Register notice 2021-18072

The Federal Register published notice 2021-18072, attributed to FDA and its parent HHS department, on 2021-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Semaglutide.

Source: Federal Register via GovInfo ↗

June 2021

3 records

Octreotide

Federal Register notice 2021-11575

The Federal Register published notice 2021-11575, attributed to FDA and its parent HHS department, on 2021-06-02. Its official title is “Determination That SANDOSTATIN (Octreotide Acetate) Injection, Equal to 0.2 Milligrams Base/Milliliter and Equal to 1 Milligrams Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.

Source: Federal Register via GovInfo ↗

May 2021

1 record

April 2021

4 records

March 2021

1 record

Bremelanotide + 1 more

Federal Register notice 2021-06202

The Federal Register published notice 2021-06202, attributed to FDA and its parent HHS department, on 2021-03-25. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Bremelanotide and Octreotide.

Source: Federal Register via GovInfo ↗

February 2021

2 records

January 2021

1 record